

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 58017

Title: Practice change in management of metastatic urothelial carcinoma after ASCO 2020

Reviewer's code: 03739641

Position: Editorial Board

Academic degree: PhD

Professional title: Nurse, Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: Spain

Manuscript submission date: 2020-07-02

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2020-10-03 23:53

Reviewer performed review: 2020-10-06 10:18

Review time: 2 Days and 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Comments to the author 1.3 The author should consistently include the country in the institution part. “1.7 Abstract Line 10 At ASCO 2020 the results of JAVELIN Bladder 100 phase 3 trial were presented,” This part is hard to understand. Please reconsider and revise it. Is “JAVELIN Bladder” a clinical trial name? If so, the author should write a consistently same spell. The author mentioned avelumab as one of the keywords of this editorial. In the abstract and core tip, the author should simply explain the feature of this drug and the relationship of this drug and JAVELIN Bladder trial. The author said “The landscape of urothelial carcinoma treatment has changed significantly in the last years.” in the core tip. Would you like to mention “in the last decades”? The author should specifically explain how long has it taken to shift the new landscape from traditional therapy. 2.1 Main Text INTRODUCTION “Urothelial carcinoma is the predominant histologic type, with approximately 90 percent of bladder cancers in the United States and Europe.” The author needs to add a reference to this sentence. “In addition, new drugs, such as immune checkpoint inhibitors (ICI) and targeted agents, have emerged as new therapeutic choices in the last years and have changed the therapy landscape of mUC.” In this sentence, the “targeted agent” should be written molecular targeted agent.” Moreover “in the last years” are vague to explain the transition of the new therapy. References 10 and 11 are the website of FDA approval. As an editorial, the author should use any trials or research abstract to this part. Please reconsider and revise those. Moreover, the author should consistently write the name of drugs small characteristics such as erdafitinib, and enfortumab vedtin. End of the introduction part, the author should explain the purpose of this editorial clearly. “MOST RELEVANT STUDIES PRESENTED AT ASCO 2020 JAVELIN Bladder 100 was one of the most important studies that were presented at ASCO 2020. ---” In this part, the author did not

write the reference for this trial. Please check and add the appropriate reference. The author should use table 1 more effectively to explain the relevant study which showed a new treatment option to mUC. Moreover, the author has to add references to table 1.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 58017

Title: Practice change in management of metastatic urothelial carcinoma after ASCO 2020

Reviewer's code: 03890335

Position: Editorial Board

Academic degree: BSc, MD

Professional title: Doctor, Research Fellow, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: Spain

Manuscript submission date: 2020-07-02

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2020-10-16 15:27

Reviewer performed review: 2020-10-17 04:50

Review time: 13 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The manuscript was well-organized, and the core tips the authors presented are useful for clinicians when using drugs.